t
Wellnex Life Limited, via its wholly owned subsidiary BSPS Aust Pty Ltd, signed an extension to its existing licensing and supply agreement with Haleon UK Trading Services Ltd and Olive Pharmascience Ltd. The agreement, originally entered into on 16 March 2022, covers the supply of soft gel liquid paracetamol products to Haleon UK and has been extended until 16 March 2027. The Board of Wellnex Life Limited authorized this announcement on 2 April 2026.
| Date | 2 Apr 2026 |
| Time | 07:00:04 |
| Category | Acquisitions and alliances |
| ID | 1603Z |
ASX/AIM Announcement
2 April 2026
Extension of Haleon Licensing and Supply Agreement
Wellnex Life Limited (ASX/AIM: WNX) ("Wellnex Life" or the "Company") is pleased to announce that the Company, through its wholly owned subsidiary BSPS Aust Pty Ltd, has signed an extension to the existing licensing and supply agreement (the "Agreement") originally entered into on 16 March 2022 between the Company, Haleon UK Trading Services Ltd ("Haleon UK") and Olive Pharmascience Ltd. The Agreement, for the supply to Haleon UK of soft gel liquid paracetamol products, has been extended until 16 March 2027.
Eric Jiang Interim Executive Chairman said, "The Company is proud to continue its global partnership with Haleon, supporting their global brands with our innovative analgesic liquid soft gels."
This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).
--- END ---
For further information, please contact:
Wellnex Life Limited (ASX/AIM:WNX)
Eric Jiang
Interim Executive Chairman
UK Investors
Strand Hanson (Financial & Nominated Advisor)
James Harris / Richard Johnson Tel: +44 (0) 20 7409 3494
Orana Corporate LLP (Joint Broker) [email protected]
Sebastian Wykeham
S.P. Angel Corporate Finance LLP (Joint Broker) Tel: +44 (0)20 3470 0470
David Hignell / Vadim Alexandre
To learn more, please visit: https://wellnexlife.com.au/